InstructorRoyed Training
TypeOnline Course
Student Enrolled4
Price$750 / 37500 INR.
Buy NowBook Now
pharma market access online course


Who should attend

Course Type




Course Deliverable


Related Courses

market access pricing

This course will provide practical understanding about the pharma market access strategies, forecasting, pricing and reimbursement. This advanced online market access and pricing course covers pharmaceutical and biopharmaceutical market access strategic management and planning process. Hence, this course will demonstrate market access skills required for pharmaceutical and biopharmaceutical organization to success. The course provides real life case based simulations for better understanding the complex issues of market access, pricing, forecasting. As a result, it is easy for participants to understand the concepts. Moreover, cutting edge simulations help participants apply the knowledge in interactive real life simulation. 

Above all, this market access training course focus on value pricing for market access which is important critical yet complex buzzword in biopharmaceutical industry. Also at the same time, course provides in-depth understanding on evidence-based pricing for pharmaceuticals. 

Pharma Market Access training is also available in 1 month advanced certification in Pharma Market Access and Pricing.

In addition, this course challenges students and Professionals to apply what they have learned through the use of interactive exercises, reflection questions, and a final assessment at the end of the course.

The course can be completed at any place. So, it allows the user to stop and start at their leisure. 

Moreover, user can access the course at own pace. It allows the user to stop and start at their leisure. 

Course Code: RYD-099

Course Title: PG Certification in Pharma Market Access (PGPMA)

Who should attend?

  • Pricing, Market Access Professionals who want to learn about regional markets.
  • Regulatory professionals who want to learn about commercial issues.
  • Strategic planners who want to know where they might go next
  • Those who want insight into the way that markets influence each other
  • Anyone who wants to understand global pricing issues

Online distance learning course. Course can be accessed online across anywhere 24×7.

1 year from the date of initiation of the course.

Graduation in any discipline.

Certificate will be provided at the end of the successful completion of the course

  1. Attend the course 24×7 by login to your dashboard. Therefore, one can attend lectures, simulation, self assessment tests and final certification examination online at own convenience.
  2. You will also be eligible to receive the course study modules, which you can download by login to your course page.

Course Features

This online course utilizes 24×7 interactive learning tools to guide each participant through the steps of market access, pricing, forecasting and reimbursement. Moreover this market access training challenges participants to apply what they have learned through the use of interactive exercises, reflection questions, expert live chat and a final assessment at the end of the course.

Important Learning Features: 

  • Online 24×7 access from anywhere. Hence, one can learn at your convenience.
  • The course provides timing flexibility. In other words, one can attend the lecture sessions at your own convenient time.
  • The course is build on interactive e-learning. Hence, it helps user to understand of the concepts effectively.
  • Above all, course provides simulation for real life working. Hence, it helps user to apply the decision making skill in real life scenarios.

Course Coverage Area

  • The course provided comprehensive advanced understanding on global and national pricing, market access, pricing, forecasting.
  • Advance practical training in health economics and evidence based pricing concepts.
  • Advance training on market assessment to determine pricing models.
  • Detailed training on forecasting models and techniques with practical case studies.
  • Training on value dossier preparation.

We also have 1 month certification course in pharmaceutical market access and pricing.

Some of the other related courses are mentioned below.

Related Courses

Followings are the few of the similar courses, you may be interested in

Section 1Market Access & Health Economics
Lecture 1Introduction to Market Access | Objectives | Various Key Terminologies | Steps of Market Access | Understanding on Pricing and Reimbursement
Lecture 2Market Access Functions : Role and Responsibilities | Key Job Areas | Understanding Job Description
Lecture 3Market Access Strategic Planning : Steps and Logical Sequencing for Market Access Strategy Development
Lecture 4Introduction to Health Economics | Key terminologies related to health economics
Lecture 5HEOR Application in Pharmaceutical and Biopharmaceutical Industry
Lecture 6Market Access Value Dossier : What it is | Significance | Components | What to include
Lecture 7Economic Evaluation Methods | Various methods | Importance of perspective in health economics | Discounting | Uncertainty 
Lecture 8Core fundamentals of Health Economics | Clinical and economic burden | Public Health Care Payer Vs. Patient and Societal | Positioning a new treatment with the current treatment | QALY | ICER | Threshold value | Clinical trials vs health economics assessment
Lecture 9QALY | How to calculate QALY | Importance and Significance 
Lecture 10ICER | How to calculate ICER | Importance and Significance | Incremental Effectiveness determination 
Lecture 11Pharmacoeconomic Evaluation Checklist | Health Economics Map | Economic evaluation cycle | Checklist of economic evaluation | Costs and Outcome relevant to different groups | Comparators | Problem of choosing the comparators
Lecture 12Pharmacoeconomic Evaluation - Resource and Cost | Fixed, Variable and Total Cost | Calculation | Average vs. marginal cost | Importance of marginal cost | Discounting | Discounting calculation | Preferable discounting rate | Sources of unit cost data | Reference costs
Lecture 13Pharmacoeconomic Evaluation - Benefits and Outcome | C/E Ratio | Intermediate Vs. Final Outcome | Sources of Effectiveness Data | QALY | Utility Weight | WTP | VPF | ATP | Difference between WTP & ATP 
Lecture 14Pharmaco-economic evaluation – analysis and results | Different Types of Models | Understanding Decision Tree - Components with practical Example | Markov model 
Lecture 15CER and PCOR
Section 2Discovery Development to Commercialization (Pharma / Biopharma R&D) - US Market
Lecture 16Pharma R&D Process & Introduction to drug discovery
Lecture 17Investigational New Drug Application (INDA)
Lecture 18New Drug Application (NDA) 
Lecture 19Biological Licensing Application (BLA)  | 351(a) application | Form 356h | Differentiation with NDA | Timeline | Handling FDA queries
Lecture 20Basic concept and understanding of the Generic Drug
Lecture 21Abbreviated New Drug Application (ANDA) 
Lecture 22Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 23Handling of orange book
Lecture 24Purple Book: Significance | Searching | Assignments
Lecture 25Clinical Trials Terminologies
Lecture 26Patent & Exclusivity - Strategic Understanding
Section 3Regulatory Landscape - Europe
Lecture 27Introduction to EU Regulation 
Lecture 28Orientation to European Countries and National Regulatory Bodies
Lecture 29EU Drug Discovery Development to Commercialization (Step By Step)
Lecture 30Overview of EU Regulation 
Lecture 31EMA and EMA Authorisation Process
Lecture 32EU MA Application Types and Strategic Planning
Lecture 33EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure 
Lecture 34EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 35Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 36Accelerated assessment by EMEA
Lecture 37EU Adaptive Pathway
Section 4Market Access Strategic Planning
Lecture 38Market Access Strategic Planning : Steps and Logical Sequencing for Market Access Strategy Development
Lecture 39Indication Sequencing | Indication Prioritization | Development of Indication Timeline | Indication Matrix | Value Based Indication Prioritization
Lecture 40Indication Prioritization Case Study
Lecture 41Market Access Value Dossier : What it is | Significance | Components | What to include
Lecture 42AMCP Market Access Dossier Preparation 
Lecture 43Target product profile (TPP) | Quality Target product profile (QTPP) | Critical Quality Attributes (CQAs) | Quality By Design (QbD)
Lecture 44Practical Training on Value Dossier Preparation | Sample Value Dossier with each section with data | Key points to consider while preparing value dossier
Lecture 45Clinical Data in Value Dossier | Understanding in different types of clinical study with rationale | Case based example on clinical study section writing
Lecture 46Budget Impact Analysis | Importance | Significance | Steps involved | Total Budget Impact Calculation | Simulation - BIA of novel molecule with real life example | Total Budget Impact Calculation for Novel Molecule 
Lecture 47Markov Model | Significance | Importance | Time horizon - Significance | Real Life Development of Markov Model | Calculation 
Section 5Pricing, Reimbursement and Formulary Placement
Lecture 48Drug Pricing Methodologies - I
Lecture 49Drug Pricing Methodologies II
Lecture 50Formulary Placement | Different Tiers | How to classify the medication in different tiers | Formulary negotiation process | Rebates | Copay differential | Step-edits | Case Simulations - teasers
Lecture 51Pharma Market Access Pricing Case Study
Lecture 52Case Study : Pharma Pricing and Reimbursement Planning for new launches | Reimbursement Rate Calculation 
Lecture 53HCPCS and CPT Codes | Importance | Significance and Characteristics | Differences between HCPCS and CPT Codes 
Section 6Forecasting and Market Size Analysis
Lecture 54Sales Forecasting in Lifesceience industry
Lecture 55New Product Forecast algorithms
Lecture 56Patient Based Forecasting Model | Applying more filters and variables
Lecture 57Prescription Based Forecasting Model | Differences between Patient Based and Prescription Based Forecasting Model | Which model to use and when?
Lecture 58Prevalence Vs. Incidence Model
Lecture 59EPI Based Forecasting | Sales Based Forecasting | When and where to apply which forecasting model
Lecture 60Sales Forecasting Tools | New Product Forecasting | In Market Forecasting
Lecture 61Market Size Assignment 1 [Oncology Brand] - Applying sales forecasting tools to carry out next 6 years sales forecast | Excel Based Model
Lecture 62Market Size Assignment 2 [Asthma Brand] - Applying sales forecasting tools to carry out multiple years sales forecast | Excel Based Model
Lecture 63Patient Based Model Vs. Patient Flow Model | Critical Differences in Model | Concept of Black Box in Patient Flow Model | Application of both model
Lecture 64Concomitancy and polypharmacy | How it alter the basic forecasting algorithm | Practical Working | Comorbidity
Lecture 65Forecasting Techniques | Simple Conjoint-type Models | Zipf's Law | Simple Elasticity Model | The Bass Model |Simple Extrapolation
Lecture 66Bottom-up or Top-down forecasting : How and When | Practical cases
Lecture 67Simulation : Bottom-up forecasting
Lecture 68Assessment on Bottom-up forecasting
Lecture 69Oncology Brand Forecasting
Lecture 70Revenue Forecasting Case Study - Novel Antihypertensive 
Lecture 71Portfolio Based Forecasting | Forecasting Model Development in Excel 
Lecture 72QALY | How to calculate QALY | Importance and Significance 
Lecture 73ICER | How to calculate ICER | Importance and Significance | Incremental Effectiveness determination 
Lecture 74Moving Average | Moving Annual Total | YTD | How to calculate 
Lecture 75Compound Annual Growth Rate | CAGR Calculation
Lecture 76First-in-class | Best-in-class | Market Access Strategic Decision Making 
Lecture 77Forecasting Biosimilar | Key Factors to consider
Lecture 78Consensus Meeting 
Lecture 79One Number Vs. Multi Number Forecasting
Lecture 80Active Vs. Passive Cannibalization | Impact on forecasting | Case Study
Section 7Real World Data and Real World Evidene
Lecture 81Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence? 
Lecture 82RWD and RWE | Potential sources of RWE | Traditional RCTs vs. RWE | Case Study - RWE Programs | Influencing HCP decision-making
Lecture 83RWE in lifescycle management
Lecture 84RWD and RWE - Fit to use | Assessment 
Lecture 85RWD data sources | Different types | Detailed understanding of each class 
Lecture 86RWE - Study Design
Lecture 87RWE - Published Tool
Section 8Business Development, Licensing & Valuation Management
Lecture 88Training on Basic Finance  |  Understanding Financial Statment | Income Statement | Balance Sheet | Cash Flow Statement
Lecture 89Business Development Job Functionality | Strategic Planning Process | Knowledge Area of Business Development | Lead targeting | Licensing term sheets
Lecture 90Portfolio Management Process | Portfolio Characteristics | Portfolio Analysis | Balancing the Portfolio | BD and Strategic Planning Department 
Lecture 91Identifying the corporate Need of business development | Objective – Strategy - Tactics | Portfolio constraints | SWOT | Numerical SWOT
Lecture 92Profiling and Searching | Objectives | Search Database | Creating Opportunity Anatomy for deal analysis | Mind Mapping | Searching Tools and Techniques - Web Search | Conference | Confidentaility - CDA | MTA
Lecture 93Numerical SWOT Practical training
Lecture 94Modelling and Deal Valuation - Top Down Model | Epidemiology data method | Complex Model | Forecasting | Heuristic or ‘prophesy’ method | Different value perspectives | Deal Structuring Structuring the deal
Lecture 95Market Size Determination - Market Share | Relative Market Share | Total Vs. Actual Vs. Penetrated Market
Lecture 96Forecasting : Tools and Techniques
Lecture 97Market Sizing & Forecasting Case Study
Lecture 98Royalty Management - Royalty structuring | Royalty Calculation Method| Tiered Royalties | Terms | Royalty Reductions | Royalty Stacking - Concept and Calculation | Minimum Annual Royalties | Reach through royalties
Lecture 99Average Royalty Rate
Lecture 100Factor affecting the Royalty Rate in Pharmaceutical and Biopharmaceutical Deal
Lecture 101Distribution Licensing | Geography | Indication Splitting | Exclusive and Non-Exclusive Licensing | Sub Licenses
Lecture 102Acquisition in Pharma  | Product Acquisition| Company Acquisitions| Steps in acquisition | Financing acquisition deals | Trademark Assignment Process
Lecture 103Joint Ventures in Pharmaceutical and Biopharmaceutical Industry
Lecture 105Indication Splitting | Concept | Implementation feasibility analysis 
Lecture 106Types of Deals from Discovery to Commercialization
Lecture 107Review: What are the fundamental areas of business development
Lecture 108Licensing Term Sheet | Content Structuring | Sample Term Sheet
Lecture 109Licensing Payment Schedule | Case Study 
Lecture 110Valuation Methods: DCF | rNPV | Sunk Cost Method | Comparables | Sum of Parts | Deterministic Vs. Probabilistic rNPV |  Peak Sales - Max-Min Approach
Lecture 111Valuation Methods: EBITDA method of valuation | Enterprise Value and Enterprise Multiple Calculation
Lecture 112Business Development Simulation and Decision Making | Early Stage VS. Late Stage Valuation Methodology | Stair Step Model
Lecture 113Licensing Agreement : Confidentiality Agreement | MTA | A deed of Assignment | Exclusive | Non-Exclusive License | Sole License | Components - Terms - Duration - Key Considerations
Lecture 114Step By Step Implementation of Licensing Deal by Business Development Team 
Lecture 115Value Share Principle | Discounting of licensing deal | Discount Rate 
Lecture 116DCF Calculation : Concept and Calculation - Step by step understanding
Lecture 117Net Present Value (NPV) method : Calculation
Lecture 118Risk-Adjusted Discount Rate Method - Calculation | Concept of Risk Premium 
Lecture 119Valuation Metric - P/E Ratio and EPS : Calculation
Lecture 120Comparable Company Analysis method : Calculation
Lecture 121EBITDA Multiples | Importance in Pharma Biopharma BD&L | Calculation | Benchmarking EBITDA multiplies | Sourcing EBITDA multiples | Decoding EBITDA multiples value in different types of pharma and biopharma organizations
Lecture 122Pipeline Benchmarking | Significance and Importance in Bio Pharma BD&L | Analyzing sample portfolio | Comparative outcome in business development 
Lecture 123Comparative pipeline benchmarking analysis | Level of Benchmarking | Primary - Secondary - Tertiary Benchmarking Metrics | Case Based Analysis of three companies comparative pipeline benchmarking
Lecture 124Pipeline Diversity Scores | Significance | How to Calculate | Comparative Study of Pipeline Diversity Scores
Lecture 125Design, Analysis, Assessment and Feedback on Real Time Portfolio Tracker
Lecture 126Research Productivity Index | Concept | Significance | Calculation Methodology | Comparative RPI benchmarking Exercise  
Section 9Request for Course Certificate